AbbVie Story

AbbVie Inc -- USA Stock  

USD 106.49  1.85  1.77%

Macroaxis does not monitor all media channels or aggregates social signals for AbbVie. But even though we do not provide professional-grade financial sentiment analysis on AbbVie Inc, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for AbbVie. Check also AbbVie Hype Analysis, AbbVie Correlation and AbbVie Performance
Acquisition by Robert Alpern of tradable shares of AbbVie subject to Rule 16b-3
Filed transaction by Abbvie Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

AbbVie Inc insider trading alert for grant of stock equivalent units by Robert Alpern, the corporate stakeholder, on January 3, 2018. This event was filed by Abbvie Inc with SEC on 2018-01-03. Statement of changes in beneficial ownership - SEC Form 4

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 0.57% . The overall trading delta when the story was published against the current closing price is 4.75% .

Similar stores for AbbVie

few hours ago at 
The sentiment expressed by investors AbbVie Inc. , Tesla, Inc.
Taking a close look at the activity of the stock of AbbVie Inc. , during the trading sessions, it is clear to see that the prices of their shares moved to 104.64.
Revenue Approximations Analysis AbbVie Inc. , The Williams Companies ...wsj  News
Investors who are keeping close eye on the stock of AbbVie Inc. established that the company was able to keep return on investment at 11.73 in the trailing twelve month while Reuters data showed that industry average stands at 15.00 and ... With An ROE Of 101.06, Has AbbVie Inc Management Done A Good Job - Simply Wall St
over a week ago at 
Analyst Predictions on Gilead Sciences, Inc. , AbbVie Inc.
wsj  News
AbbVie Inc. ended its day at 99.49 with the rising stream of -1.60 percent and its total traded volume was 5.58 million shares more than the average volume.

Did you try this?

Run Portfolio Backtesting Now

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
Hide  View All  NextLaunch Portfolio Backtesting

Price to Sales

Price to Sales Comparative Analysis
AbbVie is currently under evaluation in price to sales category among related companies. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.